{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T15:11:25Z","timestamp":1792854685099,"version":"4.5.0"},"reference-count":39,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"1","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,2]]},"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>Patients undergoing solid organ and hematopoietic stem cell transplantation are at risk of opportunistic pathogenic infections that increase morbidity and mortality. Universal antiviral prophylaxis improves the outcomes in this context. Therapeutic drug monitoring of antiviral drugs is not universally recommended but may be necessary in certain complex or polymorbid patients. The authors aimed to develop and validate a high-performance liquid chromatography\u2013tandem mass spectrometry method to simultaneously quantify ganciclovir, acyclovir, and letermovir in human serum.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>A stable isotopically labeled internal standard was used for each antiviral drug. Compounds were extracted by protein precipitation, evaporation, and reconstitution in an aqueous mobile phase. Samples were analyzed using reverse-phase chromatography with subsequent detection by electrospray ionization in the positive ion mode on a triple quadrupole mass spectrometer (run time: 6.5 minutes).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>\n                      Analytical curves for ganciclovir and acyclovir exhibited linearity within 0.1\u201325 mg\/L (R\n                      <jats:sup>2<\/jats:sup>\n                      &gt; 0.993), whereas for letermovir, the linear range was 0.01\u20132 mg\/L (R\n                      <jats:sup>2<\/jats:sup>\n                      = 0.999). Matrix effects were not observed. Intraday and interday precision and accuracy were within \u00b115%. A therapeutic drug monitoring\u2013guided strategy was explored to optimize preemptive antiviral drug therapy in 3 cohorts of transplant recipients. Seventy-nine samples from 35 patients were quantified, revealing median trough concentrations of 0.2 mg\/L for ganciclovir (n = 21), 0.28 mg\/L for acyclovir (n = 26), and 0.29 mg\/L for letermovir (n = 32).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions:<\/jats:title>\n                    <jats:p>This method has been successfully applied in clinical settings and allows reliable and accurate drug-level measurements.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/ftd.0000000000001321","type":"journal-article","created":{"date-parts":[[2025,3,18]],"date-time":"2025-03-18T11:01:17Z","timestamp":1742295677000},"page":"119-126","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":2,"title":["Simultaneous Monitoring of 3 Antiviral Drugs in Serum Using Liquid Chromatography\u2013Tandem Mass Spectrometry: Full Validation and Clinical Application"],"prefix":"10.1097","volume":"48","author":[{"given":"Laura","family":"Conesa","sequence":"first","affiliation":[{"name":"Clinical Biochemistry Department Vall D\u2019Hebron University Hospital. Clinical Biochemistry, Drug Delivery and Therapy Research Group. Vall D\u2019Hebr\u00f3n Research Institute (VHIR), Vall D\u2019Hebron Barcelona Hospital Campus, Barcelona, Spain; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gonzalo","family":"Gonzalez-Silva","sequence":"additional","affiliation":[{"name":"Clinical Biochemistry Department Vall D\u2019Hebron University Hospital. Clinical Biochemistry, Drug Delivery and Therapy Research Group. Vall D\u2019Hebr\u00f3n Research Institute (VHIR), Vall D\u2019Hebron Barcelona Hospital Campus, Barcelona, Spain; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lydia","family":"Peris-Serra","sequence":"additional","affiliation":[{"name":"Clinical Biochemistry Department Vall D\u2019Hebron University Hospital. Clinical Biochemistry, Drug Delivery and Therapy Research Group. Vall D\u2019Hebr\u00f3n Research Institute (VHIR), Vall D\u2019Hebron Barcelona Hospital Campus, Barcelona, Spain; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarai","family":"Garriga-Edo","sequence":"additional","affiliation":[{"name":"Clinical Biochemistry Department Vall D\u2019Hebron University Hospital. Clinical Biochemistry, Drug Delivery and Therapy Research Group. Vall D\u2019Hebr\u00f3n Research Institute (VHIR), Vall D\u2019Hebron Barcelona Hospital Campus, Barcelona, Spain; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Castellote","sequence":"additional","affiliation":[{"name":"Clinical Biochemistry Department Vall D\u2019Hebron University Hospital. Clinical Biochemistry, Drug Delivery and Therapy Research Group. Vall D\u2019Hebr\u00f3n Research Institute (VHIR), Vall D\u2019Hebron Barcelona Hospital Campus, Barcelona, Spain; and"},{"name":"Biochemistry and Molecular Biology Department, Universitat Aut\u00f2noma de Barcelona (UAB), Barcelona, Spain."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roser","family":"Ferrer","sequence":"additional","affiliation":[{"name":"Clinical Biochemistry Department Vall D\u2019Hebron University Hospital. Clinical Biochemistry, Drug Delivery and Therapy Research Group. Vall D\u2019Hebr\u00f3n Research Institute (VHIR), Vall D\u2019Hebron Barcelona Hospital Campus, Barcelona, Spain; and"},{"name":"Biochemistry and Molecular Biology Department, Universitat Aut\u00f2noma de Barcelona (UAB), Barcelona, Spain."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yolanda","family":"Villena","sequence":"additional","affiliation":[{"name":"Clinical Biochemistry Department Vall D\u2019Hebron University Hospital. Clinical Biochemistry, Drug Delivery and Therapy Research Group. Vall D\u2019Hebr\u00f3n Research Institute (VHIR), Vall D\u2019Hebron Barcelona Hospital Campus, Barcelona, Spain; and"},{"name":"Biochemistry and Molecular Biology Department, Universitat Aut\u00f2noma de Barcelona (UAB), Barcelona, Spain."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2025,3,18]]},"reference":[{"key":"R1-20260108","doi-asserted-by":"crossref","first-page":"e2370","DOI":"10.3390\/v14112370","article-title":"Adoptive immunotherapy for prophylaxis and treatment of cytomegalovirus infection","volume":"14","author":"Ouellette","year":"2022","journal-title":"Viruses"},{"key":"R2-20260108","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1097\/MOT.0000000000001139","article-title":"Recent advances in cytomegalovirus infection management in solid organ transplant recipients","volume":"29","author":"Grossi","year":"2024","journal-title":"Curr Opin Organ Transpl."},{"key":"R3-20260108","doi-asserted-by":"crossref","first-page":"e13977","DOI":"10.1111\/tid.13977","article-title":"Cytomegalovirus in the transplant setting: where are we now and what happens next? A report from the International CMV Symposium 2021","volume":"24","author":"Kotton","year":"2022","journal-title":"Transpl Infect Dis."},{"key":"R4-20260108","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1097\/FTD.0000000000000925","article-title":"Therapeutic drug monitoring of ganciclovir: where are we?","volume":"44","author":"M\u00e4rtson","year":"2022","journal-title":"Ther Drug Monit."},{"key":"R5-20260108","doi-asserted-by":"crossref","first-page":"e11785","DOI":"10.3389\/ti.2023.11785","article-title":"New treatment options for refractory\/resistant CMV infection","volume":"36","author":"Walti","year":"2023","journal-title":"Transpl Int."},{"key":"R6-20260108","doi-asserted-by":"crossref","first-page":"e13733","DOI":"10.1111\/tid.13733","article-title":"Management of ganciclovir resistance cytomegalovirus infection with CMV hyperimmune globulin and leflunomide in seven cardiothoracic transplant recipients and literature review","volume":"24","author":"Santhanakrishnan","year":"2022","journal-title":"Transpl Infect Dis."},{"key":"R7-20260108","doi-asserted-by":"crossref","first-page":"e14000","DOI":"10.1111\/tid.14000","article-title":"Burden of neutropenia and leukopenia among adult kidney transplant recipients: a systematic literature review of observational studies","volume":"25","author":"Raval","year":"2023","journal-title":"Transpl Infect Dis official J Transplant Soc."},{"key":"R8-20260108","doi-asserted-by":"crossref","first-page":"1162","DOI":"10.1097\/INF.0000000000004484","article-title":"Nephrotoxicity of intravenous ganciclovir in pediatric hematopoietic cell transplant recipients","volume":"43","author":"Inagaki","year":"2024","journal-title":"Pediatr Infect Dis J."},{"key":"R9-20260108","doi-asserted-by":"crossref","first-page":"e6566","DOI":"10.3390\/molecules26216566","article-title":"Critical review of synthesis, toxicology and detection of acyclovir","volume":"26","author":"Wei","year":"2021","journal-title":"Molecules"},{"key":"R10-20260108","doi-asserted-by":"crossref","first-page":"e3431","DOI":"10.3390\/ijms23073431","article-title":"40 Years after the registration of acyclovir: do we need new anti-herpetic drugs?","volume":"23","author":"Majewska","year":"2022","journal-title":"Int J Mol Sci."},{"key":"R11-20260108","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1097\/TP.0000000000002191","article-title":"The Third International Consensus Guidelines on the management of cytomegalovirus in solid-organ transplantation","volume":"102","author":"Kotton","year":"2018","journal-title":"Transplantation"},{"key":"R12-20260108","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1136\/pn-2022-003597","article-title":"Aciclovir-induced neurotoxicity","volume":"23","author":"Vonberg","year":"2023","journal-title":"Pract Neurol."},{"key":"R13-20260108","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.cmi.2022.07.001","article-title":"Cytomegalovirus infection in transplant recipients: newly approved additions to our armamentarium","volume":"29","author":"Khawaja","year":"2023","journal-title":"Clin Microbiol Infect."},{"key":"R14-20260108","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1080\/13543784.2017.1274733","article-title":"Letermovir for the management of cytomegalovirus infection","volume":"26","author":"Bowman","year":"2017","journal-title":"Expert Opin Investig Drugs"},{"key":"R15-20260108","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1097\/INF.0000000000004208","article-title":"Pharmacokinetics, safety, and efficacy of letermovir for cytomegalovirus prophylaxis in adolescent hematopoietic cell transplantation recipients","volume":"43","author":"Groll","year":"2024","journal-title":"Pediatr Infect Dis J."},{"key":"R16-20260108","doi-asserted-by":"crossref","first-page":"e00178","DOI":"10.1097\/BS9.0000000000000178","article-title":"Efficacy and safety of letermovir prophylaxis for cytomegalovirus infection after hematopoietic stem cell transplantation","volume":"6","author":"Li","year":"2024","journal-title":"Blood Sci."},{"key":"R17-20260108","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/S2352-3026(23)00344-7","article-title":"Efficacy and safety of extended duration letermovir prophylaxis in recipients of haematopoietic stem-cell transplantation at risk of cytomegalovirus infection: a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial","volume":"11","author":"Russo","year":"2024","journal-title":"Lancet Haematol."},{"key":"R18-20260108","doi-asserted-by":"crossref","first-page":"e14279","DOI":"10.1111\/tid.14279","article-title":"Evaluating the efficacy and safety of letermovir compared to valganciclovir for the prevention of human cytomegalovirus disease in adult lung transplant recipients","volume":"26","author":"Martinez","year":"2024","journal-title":"Transpl Infect Dis."},{"key":"R19-20260108","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1001\/jama.2023.9106","article-title":"Letermovir vs valganciclovir for prophylaxis of cytomegalovirus in high-risk kidney transplant recipients: a randomized clinical trial","volume":"330","author":"Limaye","year":"2023","journal-title":"JAMA"},{"key":"R20-20260108","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1097\/QCO.0000000000000965","article-title":"Evidence supporting the use of therapeutic drug monitoring of ganciclovir in transplantation","volume":"36","author":"Wong","year":"2023","journal-title":"Curr Opin Infect Dis."},{"key":"R21-20260108","doi-asserted-by":"crossref","first-page":"e13512","DOI":"10.1111\/ctr.13512","article-title":"Cytomegalovirus in solid organ transplant recipients-guidelines of the American society of transplantation infectious diseases community of practice","volume":"33","author":"Razonable","year":"2019","journal-title":"Clin Transpl."},{"key":"R22-20260108","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1016\/S1473-3099(19)30107-0","article-title":"Guidelines for the management of cytomegalovirus infection in patients with haematological malignancies and after stem cell transplantation from the 2017 European Conference on Infections in Leukaemia (ECIL 7)","volume":"19","author":"Ljungman","year":"2019","journal-title":"Lancet Infect Dis."},{"key":"R23-20260108","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1016\/j.jchromb.2008.04.022","article-title":"Simultaneous determination of aciclovir, ganciclovir, and penciclovir in human plasma by high-performance liquid chromatography with fluorescence detection","volume":"867","author":"Dao","year":"2008","journal-title":"J Chromatogr B Analyt Technol Biomed Life Sci."},{"key":"R24-20260108","doi-asserted-by":"crossref","first-page":"e1379","DOI":"10.3390\/biomedicines9101379","article-title":"A UHPLC\u2013MS\/MS method for therapeutic drug monitoring of aciclovir and ganciclovir in plasma and dried plasma spots","volume":"9","author":"Pigliasco","year":"2021","journal-title":"Biomedicines"},{"key":"R25-20260108","doi-asserted-by":"crossref","first-page":"e5315","DOI":"10.1002\/bmc.5315","article-title":"Rapid determination of acyclovir, its main metabolite 9\u2010carboxymethoxymethylguanine, ganciclovir, and penciclovir in human serum using LC\u2013MS\/MS","volume":"36","author":"\u00c4rlemalm","year":"2022","journal-title":"Biomed Chromatogr."},{"key":"R26-20260108","doi-asserted-by":"crossref","first-page":"e2685","DOI":"10.3390\/ijms25052685","article-title":"Development and validation of an HPLC-UV method for the quantification of acyclovir and ganciclovir in the plasma of pediatric immunocompromised patients","volume":"25","author":"Franzin","year":"2024","journal-title":"Int J Mol Sci."},{"key":"R27-20260108","doi-asserted-by":"crossref","first-page":"e122399","DOI":"10.1016\/j.jchromb.2020.122399","article-title":"Quantification of letermovir in human serum using high-performance liquid chromatography with diode array detection","volume":"1159","author":"Isberner","year":"2020","journal-title":"J Chromatogr B, Anal Tech Biomed Life Sci."},{"key":"R28-20260108","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1248\/cpb.c21-00142","article-title":"Development and full validation of a bioanalytical method for quantifying letermovir in human plasma using ultra-performance liquid chromatography coupled with mass spectrometry","volume":"69","author":"Belabbas","year":"2021","journal-title":"Chem Pharm Bull."},{"key":"R30-20260108","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1016\/j.jchromb.2007.01.045","article-title":"Determination of aciclovir and ganciclovir in human plasma by liquid chromatography\u2013spectrofluorimetric detection and stability studies in blood samples","volume":"852","author":"Perrottet","year":"2007","journal-title":"J Chromatogr B Analyt Technol Biomed Life Sci."},{"key":"R31-20260108","doi-asserted-by":"crossref","first-page":"e113852","DOI":"10.1016\/j.biopha.2022.113852","article-title":"Therapeutic monitoring of serum concentrations of acyclovir and its metabolite 9-(carboxymethoxymethyl) guanine in routine clinical practice","volume":"156","author":"Kacirova","year":"2022","journal-title":"Biomed Pharmacother."},{"key":"R32-20260108","doi-asserted-by":"crossref","first-page":"e14141","DOI":"10.1111\/tid.14141","article-title":"Trough ganciclovir concentration as predictor of leukopenia in lung transplant recipients receiving valganciclovir prophylaxis","volume":"25","author":"Katada","year":"2023","journal-title":"Transpl Infect Dis."},{"key":"R33-20260108","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1111\/j.1399-0012.2009.01205.x","article-title":"Ganciclovir exposure under a 450 mg daily dosage of valganciclovir for cytomegalovirus prevention in kidney transplantation: a prospective study","volume":"24","author":"Manuel","year":"2010","journal-title":"Clin Transpl."},{"key":"R34-20260108","doi-asserted-by":"crossref","first-page":"e0065722","DOI":"10.1128\/aac.00657-22","article-title":"Therapeutic drug monitoring of orally administered letermovir prophylaxis in allogeneic hematopoietic stem cell transplant recipients","volume":"66","author":"Royston","year":"2022","journal-title":"Antimicrob Agents Chemother."},{"key":"R35-20260108","doi-asserted-by":"crossref","first-page":"2433","DOI":"10.1056\/NEJMoa1706640","article-title":"Letermovir prophylaxis for cytomegalovirus in hematopoietic-cell transplantation","volume":"377","author":"Marty","year":"2017","journal-title":"N Engl J Med."},{"key":"R36-20260108","doi-asserted-by":"crossref","first-page":"2356","DOI":"10.1093\/jac\/dkab195","article-title":"Ganciclovir therapeutic drug monitoring in transplant recipients","volume":"76","author":"M\u00e4rtson","year":"2021","journal-title":"J Antimicrob Chemother."},{"key":"R37-20260108","doi-asserted-by":"crossref","first-page":"018555-18","DOI":"10.1128\/AAC.01855-18","article-title":"Relationship of ganciclovir therapeutic drug monitoring with clinical efficacy and patient safety","volume":"63","author":"Ritchie","year":"2019","journal-title":"Antimicrob Agents Chemother."},{"key":"R38-20260108","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/j.antiviral.2017.09.013","article-title":"Recurrent herpetic keratitis despite antiviral prophylaxis: a virological and pharmacological study","volume":"146","author":"Rousseau","year":"2017","journal-title":"Antivir Res"},{"key":"R39-20260108","first-page":"96","article-title":"Compassionate use of letermovir in a 2-year-old immunocompromised child with resistant cytomegalovirus disease","volume":"9","author":"P\u00e9rez Mar\u00edn","year":"2020","journal-title":"J Pediatr Infect Dis Soc"},{"key":"R40-20260108","doi-asserted-by":"crossref","first-page":"2820","DOI":"10.1093\/jac\/dkz218","article-title":"Letermovir in paediatric HSCT recipients","volume":"74","author":"Strenger","year":"2019","journal-title":"J Antimicrob Chemother."}],"container-title":["Therapeutic Drug Monitoring"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/FTD.0000000000001321","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,8]],"date-time":"2026-01-08T05:01:36Z","timestamp":1767848496000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/FTD.0000000000001321"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,18]]},"references-count":39,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.1097\/ftd.0000000000001321","relation":{},"ISSN":["0163-4356","1536-3694"],"issn-type":[{"value":"0163-4356","type":"print"},{"value":"1536-3694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,18]]},"assertion":[{"value":"2024-12-03","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-02-05","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}